Rasburicase recalls
The FDA has published 1 recall involving Rasburicase since 2020. The latest was reported on 26 Aug 2020. Most were for potency & assay. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls1since 2020
Last 12 months0reported
Class I00% of total
Ongoing1latest 26 Aug 2020
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 1 100%Class III 0 0%
Why rasburicase is recalled
Companies
By year
Ongoing rasburicase recalls
1 active| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Elitek (rasburicase) for injection, 7.5 mg vial recalledElitek | Sanofi-Aventis U.S | Potency & Assay | Nationwide |
All rasburicase recalls, newest first
1 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Elitek (rasburicase) for injection, 7.5 mg vial recalledElitek | Sanofi-Aventis U.S | Potency & Assay | Nationwide |
Should you stop taking Rasburicase?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.